THE SMART TRICK OF ABBV-744 PRECLINICAL STUDIES AND RESULTS THAT NOBODY IS DISCUSSING

In Segment A, individuals will receive different doses and schedules of oral ABBV-744 pill to establish Risk-free dosing regimen. Additional contributors are going to be enrolled on the identified monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "increase-on" therapy. In Sect